FORM 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2011

 

 

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

 

 

Commission File Number: 001-34207

 

Delaware   33-0728374

(State or other jurisdiction

of incorporation)

  

(IRS Employer

Identification No.)

2929 Seventh Street, Suite 100

Berkeley, CA 94710-2753

(Address of principal executive offices, including zip code)

(510) 848-5100

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01 Other Events

On September 18, 2011, Dynavax Technologies Corporation (Dynavax) issued a press release titled “Dynavax Reports Complete Results from the HEPLISAV™ Phase 3 Trial in Healthy Adults Over Age 40” and presented complete results for the entire study population of its Phase 3 trial (HBV-16) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, IL. A copy of the press release and the presentation are attached as Exhibit 99.1 and 99.2, respectively, to this current report and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibit

 

Exhibit No.    Description
99.1    Press Release, dated September 18, 2011, titled “Dynavax Reports Complete Results from the HEPLISAV™ Phase 3 Trial in Healthy Adults Over Age 40”
99.2    Dynavax’s Oral Presentation at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    DYNAVAX TECHNOLOGIES CORPORATION

Date: September 21, 2011

     By:   /s/ Michael S. Ostrach
      Michael S. Ostrach
      Vice President

EXHIBIT INDEX

 

Exhibit No.    Description
99.1    Press Release, dated September 18, 2011, titled “Dynavax Reports Complete Results from the HEPLISAV™ Phase 3 Trial in Healthy Adults Over Age 40”
99.2    Dynavax’s Oral Presentation at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)